Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.990
+0.090 (3.10%)
At close: Sep 18, 2025, 4:00 PM EDT
2.970
-0.020 (-0.67%)
After-hours: Sep 18, 2025, 7:33 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $815.66 million as of September 18, 2025. Its market cap has increased by 77.67% in one year.
Market Cap
815.66M
Enterprise Value
562.66M
1-Year Change
77.67%
Ranking
Category
Stock Price
$2.99
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $815.66M, an increase of 18.14%. That is a compound annual growth rate of 3.40%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 17, 2025 | 791.11M | 123.13% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | 1.00B | 45.15% |
| Sep 24, 2020 | 690.43M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 682.40B |
| Johnson & Johnson | 426.76B |
| AbbVie | 390.07B |
| UnitedHealth Group | 309.39B |
| Novo Nordisk | 260.64B |
| AstraZeneca | 241.43B |
| Novartis AG | 237.64B |
| Abbott Laboratories | 233.52B |